IDH2 and angioimmunoblastic T-cell lymphoma: We previously reported a rapid and durable (>5 years) remission following AZA in a RR-AITL patient with TP53 disruption and no mutation or copy number variation in TET family hydroxymethylases, DNMT3A or IDH2 [11].